New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
09:01 EDTGALTGalectin Therapeutics announces collaborative drug discovery program
Galectin Therapeutics announced the establishment of a collaborative drug discovery program with Dr. Geert-Jan Boons' laboratory located in the Complex Carbohydrate Research Center at the University of Georgia. This program is focused on the discovery of new carbohydrate molecules that can be used in the therapy of diseases where galectin proteins play a major role, including cancer and inflammatory and fibrotic disorders.
News For GALT From The Last 14 Days
Check below for free stories on GALT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
10:21 EDTGALTGalectin Therapeutics announces first patient dosed in GR-MD-02 trial
Galectin Therapeutics announced that the first patient in cohort 2 of its Phase 1 clinical trial of GR-MD-02 in patients with NASH with advanced fibrosis has been successfully dosed with 4 mg/kg, which is double the dose given in cohort 1. Cohort 2, as with all phases of the clinical trial, was initiated in full compliance with the rules, regulations, and specific conditions set forth by the U.S. Food and Drug Administration for this Phase 1 clinical trial. The second cohort follows highly successful results from the first cohort showing that 2 mg/kg was safe and very well tolerated, and that GR-MD-02 treatment resulted in significant improvement in multiple biomarkers of fibrosis and liver inflammation in patients with NASH with advanced fibrosis. The remaining patients in cohort 2 are expected to be enrolled over the next few weeks and we anticipate reporting the results of cohort 2 around the end of July.
April 7, 2014
11:15 EDTGALT Options with decreasing implied volatility: MNKD GALT DLLR APOL
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use